Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer
NL-OMON58784Phase 3Active, not recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Mar 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoint: Progression-free survival. Started Mar 2023; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58784.